Overview
- Todd, P.A. and Benfield, P. (1989) Drugs. 38, 481.
- Tytgat, J. et al. (1988) Naunyn-Schmiedeberg's Arch.Pharmacol. 337, 690.
Alomone Labs Flunarizine dihydrochloride blocks L-type Ca2+ currents in Xenopus oocytes.A. Time course of L-type channel (CaV1.2+α2δ1+β1a) activity before and during applications of 10 and 100 μM Flunarizine dihydrochloride (#F-110) and upon wash. Holding potential was -100 mV and currents were elicited every 10 seconds by 100 ms steps to 0 mV. Periods of compound application are indicated by the horizontal bars. B. Example of superimposed current traces before and during application of 10 and 100 μM Flunarizine dihydrochloride (taken from the experiment described in A).
- Haller, H. (2008) Int. J. Clin. Pract. 62, 781.
- Hockerman, G. H. et al. (1997) Annu. Rev. Pharmacol. Toxicol. 37, 361.
- Todd, P.A. and Benfield, P. (1989) Drugs. 38, 481.
- Tytgat, J. et al. (1988) Naunyn-Schmiedeberg's Arch.Pharmacol. 337, 690.
L-type (CaV1), voltage-gated Ca2+ channels are plasma membrane protein complexes which allow the passage of Ca2+ ions into cells following depolarization of the membrane potential. L-type channels are widely expressed in cardiac and smooth muscle in which they control contraction and therefore were recognized as a therapeutic target for cardiovascular diseases1,2.
Flunarizine dihydrochloride is a diphenylmethylpiperazine L-type, voltage-gated Ca2+ channel blocker and is used in the clinic to treat migraine3. Flunarizine dihydrochloride inhibits L- and T-type CaV channels in guinea pig ventricular cells with similar potency and in a use dependent manner4.
Flunarizine dihydrochloride (#F-110) is a highly pure, synthetic, and biologically active compound.
Powered by Bioz
